Stefan Sillau
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 23 | 2026 | 601 | 2.170 |
Why?
| | Epilepsies, Partial | 7 | 2026 | 63 | 1.380 |
Why?
| | Seizures | 12 | 2026 | 485 | 1.090 |
Why?
| | Alzheimer Disease | 6 | 2025 | 630 | 1.090 |
Why?
| | Multiple Sclerosis | 9 | 2025 | 489 | 1.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2025 | 161 | 0.900 |
Why?
| | Drug Resistant Epilepsy | 5 | 2026 | 140 | 0.830 |
Why?
| | Palliative Care | 13 | 2026 | 1022 | 0.830 |
Why?
| | Quality of Life | 18 | 2026 | 3210 | 0.750 |
Why?
| | Epilepsy | 5 | 2024 | 390 | 0.620 |
Why?
| | Caregivers | 9 | 2024 | 1074 | 0.560 |
Why?
| | Middle Aged | 56 | 2026 | 36302 | 0.510 |
Why?
| | Neurons | 1 | 2025 | 1652 | 0.480 |
Why?
| | Humans | 114 | 2026 | 145763 | 0.480 |
Why?
| | Cognition | 8 | 2025 | 1271 | 0.470 |
Why?
| | Natalizumab | 4 | 2021 | 41 | 0.470 |
Why?
| | Aged | 44 | 2026 | 26215 | 0.470 |
Why?
| | Stroke | 5 | 2026 | 1271 | 0.460 |
Why?
| | Aging | 2 | 2025 | 1973 | 0.450 |
Why?
| | Male | 72 | 2026 | 73003 | 0.440 |
Why?
| | Parkinsonian Disorders | 3 | 2020 | 43 | 0.440 |
Why?
| | Healthcare Disparities | 4 | 2026 | 736 | 0.430 |
Why?
| | Fingolimod Hydrochloride | 3 | 2020 | 40 | 0.430 |
Why?
| | Female | 72 | 2026 | 79035 | 0.420 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 468 | 0.410 |
Why?
| | Anticonvulsants | 3 | 2026 | 246 | 0.410 |
Why?
| | Aged, 80 and over | 20 | 2026 | 8346 | 0.400 |
Why?
| | Retrospective Studies | 36 | 2026 | 17325 | 0.400 |
Why?
| | Young Adult | 26 | 2026 | 14251 | 0.390 |
Why?
| | Adult | 44 | 2026 | 40872 | 0.390 |
Why?
| | Immunologic Factors | 3 | 2020 | 260 | 0.370 |
Why?
| | Psychotherapy, Group | 2 | 2026 | 79 | 0.370 |
Why?
| | Atherosclerosis | 4 | 2019 | 409 | 0.350 |
Why?
| | Cognition Disorders | 3 | 2024 | 544 | 0.350 |
Why?
| | Charcot-Marie-Tooth Disease | 2 | 2022 | 22 | 0.330 |
Why?
| | Cannabidiol | 2 | 2024 | 142 | 0.330 |
Why?
| | Diabetic Neuropathies | 2 | 2023 | 100 | 0.330 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1137 | 0.320 |
Why?
| | Chagas Disease | 2 | 2021 | 42 | 0.320 |
Why?
| | Ambulatory Care | 3 | 2020 | 610 | 0.320 |
Why?
| | Music Therapy | 2 | 2021 | 24 | 0.320 |
Why?
| | Sinusitis | 3 | 2021 | 227 | 0.320 |
Why?
| | Rural Health Services | 2 | 2025 | 138 | 0.290 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 0.290 |
Why?
| | Torticollis | 2 | 2019 | 17 | 0.290 |
Why?
| | Meningitis, Cryptococcal | 2 | 2019 | 34 | 0.280 |
Why?
| | Emergency Medical Services | 2 | 2026 | 684 | 0.280 |
Why?
| | Rituximab | 2 | 2020 | 210 | 0.280 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 83 | 0.280 |
Why?
| | Dystonic Disorders | 2 | 2019 | 27 | 0.280 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 79 | 0.270 |
Why?
| | Adolescent | 21 | 2026 | 22573 | 0.270 |
Why?
| | Cardiomyopathies | 2 | 2021 | 335 | 0.250 |
Why?
| | Medical Staff, Hospital | 2 | 2021 | 80 | 0.250 |
Why?
| | Spirituality | 4 | 2021 | 88 | 0.250 |
Why?
| | Myelitis | 2 | 2018 | 107 | 0.240 |
Why?
| | Treatment Outcome | 17 | 2026 | 11793 | 0.240 |
Why?
| | Cannabis | 2 | 2024 | 510 | 0.240 |
Why?
| | Chlorophenols | 1 | 2026 | 12 | 0.240 |
Why?
| | Dissociative Disorders | 1 | 2026 | 30 | 0.240 |
Why?
| | Colorado | 14 | 2025 | 4556 | 0.240 |
Why?
| | Tetrazoles | 1 | 2026 | 50 | 0.230 |
Why?
| | Carbamates | 1 | 2026 | 50 | 0.230 |
Why?
| | Suburban Health Services | 1 | 2025 | 4 | 0.230 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.220 |
Why?
| | Sepsis | 2 | 2022 | 664 | 0.220 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 122 | 0.220 |
Why?
| | Neurosurgical Procedures | 2 | 2017 | 202 | 0.220 |
Why?
| | Urban Health Services | 1 | 2025 | 69 | 0.220 |
Why?
| | Rural Health | 1 | 2025 | 87 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 11 | 2024 | 3915 | 0.220 |
Why?
| | Stiff-Person Syndrome | 1 | 2024 | 14 | 0.220 |
Why?
| | Candidemia | 1 | 2024 | 16 | 0.220 |
Why?
| | Prevalence | 9 | 2024 | 2874 | 0.210 |
Why?
| | Arterial Occlusive Diseases | 1 | 2025 | 90 | 0.210 |
Why?
| | Thrombectomy | 1 | 2025 | 78 | 0.210 |
Why?
| | Candida | 1 | 2024 | 46 | 0.210 |
Why?
| | Vulnerable Populations | 1 | 2026 | 176 | 0.210 |
Why?
| | Ischemic Attack, Transient | 1 | 2025 | 71 | 0.210 |
Why?
| | Brain | 6 | 2023 | 2969 | 0.210 |
Why?
| | Nasal Polyps | 2 | 2016 | 59 | 0.210 |
Why?
| | Adaptation, Psychological | 5 | 2020 | 719 | 0.210 |
Why?
| | Aquaporin 4 | 1 | 2024 | 101 | 0.200 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 11 | 0.200 |
Why?
| | Cell Death | 1 | 2025 | 382 | 0.200 |
Why?
| | Dronabinol | 2 | 2024 | 249 | 0.200 |
Why?
| | Community Health Services | 1 | 2026 | 231 | 0.200 |
Why?
| | Child Abuse | 2 | 2022 | 553 | 0.200 |
Why?
| | Brain Ischemia | 2 | 2025 | 359 | 0.200 |
Why?
| | Dimethyl Fumarate | 2 | 2020 | 12 | 0.200 |
Why?
| | Patient Reported Outcome Measures | 2 | 2026 | 498 | 0.200 |
Why?
| | Telemedicine | 2 | 2024 | 966 | 0.200 |
Why?
| | Cost of Illness | 3 | 2021 | 324 | 0.200 |
Why?
| | Child | 16 | 2025 | 22739 | 0.190 |
Why?
| | Risk Assessment | 7 | 2026 | 3752 | 0.190 |
Why?
| | Self Report | 4 | 2025 | 876 | 0.190 |
Why?
| | Fatigue | 1 | 2025 | 365 | 0.190 |
Why?
| | Patient Discharge | 3 | 2026 | 995 | 0.190 |
Why?
| | Inpatients | 3 | 2021 | 553 | 0.190 |
Why?
| | Cohort Studies | 10 | 2026 | 6032 | 0.190 |
Why?
| | Neuromyelitis Optica | 1 | 2024 | 140 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2026 | 321 | 0.190 |
Why?
| | Patient Care Team | 3 | 2019 | 697 | 0.190 |
Why?
| | Quality Indicators, Health Care | 1 | 2025 | 336 | 0.180 |
Why?
| | Severity of Illness Index | 8 | 2020 | 2933 | 0.180 |
Why?
| | Migraine Disorders | 1 | 2024 | 114 | 0.180 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1101 | 0.180 |
Why?
| | Apolipoprotein E4 | 1 | 2022 | 42 | 0.180 |
Why?
| | Conversion Disorder | 1 | 2022 | 10 | 0.180 |
Why?
| | Vagus Nerve Stimulation | 1 | 2022 | 28 | 0.180 |
Why?
| | Frontotemporal Dementia | 1 | 2022 | 55 | 0.180 |
Why?
| | Biomarkers | 4 | 2025 | 4302 | 0.170 |
Why?
| | Memory Consolidation | 1 | 2021 | 14 | 0.170 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 27 | 0.170 |
Why?
| | Motor Disorders | 1 | 2021 | 17 | 0.170 |
Why?
| | Atrophy | 4 | 2024 | 199 | 0.170 |
Why?
| | Dermatitis, Seborrheic | 1 | 2020 | 5 | 0.170 |
Why?
| | Interleukin-6 | 1 | 2025 | 779 | 0.170 |
Why?
| | Risk Factors | 12 | 2026 | 10917 | 0.160 |
Why?
| | Guideline Adherence | 1 | 2025 | 587 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1217 | 0.160 |
Why?
| | Basal Ganglia Diseases | 1 | 2020 | 9 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2022 | 179 | 0.160 |
Why?
| | Sleep | 3 | 2021 | 889 | 0.160 |
Why?
| | Vitamin D | 2 | 2015 | 404 | 0.160 |
Why?
| | Endovascular Procedures | 1 | 2025 | 390 | 0.160 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 28 | 0.160 |
Why?
| | Incidence | 6 | 2024 | 2933 | 0.160 |
Why?
| | Disease Progression | 4 | 2022 | 2865 | 0.160 |
Why?
| | Cytokines | 3 | 2022 | 2069 | 0.160 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 5922 | 0.150 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.150 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.150 |
Why?
| | Time Factors | 8 | 2026 | 7133 | 0.150 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2022 | 115 | 0.150 |
Why?
| | Neurovascular Coupling | 1 | 2019 | 10 | 0.150 |
Why?
| | Attitude of Health Personnel | 2 | 2021 | 1197 | 0.150 |
Why?
| | Terminal Care | 1 | 2023 | 283 | 0.150 |
Why?
| | Behavioral Symptoms | 1 | 2019 | 41 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 222 | 0.150 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 18 | 0.140 |
Why?
| | Shock, Septic | 1 | 2021 | 227 | 0.140 |
Why?
| | Critical Care Outcomes | 1 | 2018 | 11 | 0.140 |
Why?
| | Electronic Health Records | 2 | 2021 | 1202 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2602 | 0.140 |
Why?
| | Blepharospasm | 1 | 2018 | 7 | 0.140 |
Why?
| | Restless Legs Syndrome | 1 | 2018 | 20 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 39 | 0.140 |
Why?
| | Streptococcal Infections | 1 | 2021 | 171 | 0.140 |
Why?
| | Depression | 3 | 2026 | 1557 | 0.140 |
Why?
| | Cannabinoids | 1 | 2020 | 184 | 0.140 |
Why?
| | Fluoxetine | 1 | 2018 | 56 | 0.140 |
Why?
| | Proxy | 1 | 2018 | 36 | 0.140 |
Why?
| | Psychometrics | 2 | 2019 | 731 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 222 | 0.130 |
Why?
| | Basal Ganglia | 1 | 2018 | 57 | 0.130 |
Why?
| | United States | 11 | 2026 | 16123 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.130 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2018 | 78 | 0.130 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4568 | 0.130 |
Why?
| | Electroencephalography | 4 | 2022 | 563 | 0.130 |
Why?
| | Nutrition Surveys | 1 | 2019 | 279 | 0.130 |
Why?
| | Neurology | 1 | 2019 | 117 | 0.130 |
Why?
| | Subthalamic Nucleus | 1 | 2018 | 84 | 0.130 |
Why?
| | Child, Preschool | 5 | 2025 | 11868 | 0.130 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2017 | 67 | 0.130 |
Why?
| | Down Syndrome | 2 | 2022 | 525 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 838 | 0.130 |
Why?
| | Cranial Nerve Diseases | 1 | 2017 | 44 | 0.130 |
Why?
| | Apoptosis | 1 | 2025 | 2443 | 0.130 |
Why?
| | Rats | 1 | 2025 | 5585 | 0.130 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2017 | 50 | 0.130 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 269 | 0.120 |
Why?
| | Interprofessional Relations | 1 | 2019 | 276 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2021 | 892 | 0.120 |
Why?
| | Movement Disorders | 1 | 2017 | 69 | 0.120 |
Why?
| | Medical Marijuana | 1 | 2018 | 122 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 109 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2022 | 423 | 0.120 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 8 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 145 | 0.120 |
Why?
| | Orbital Diseases | 1 | 2016 | 37 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 560 | 0.120 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5428 | 0.120 |
Why?
| | Cerebellum | 1 | 2018 | 224 | 0.120 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 30 | 0.120 |
Why?
| | Meningioma | 1 | 2016 | 88 | 0.110 |
Why?
| | Meningeal Neoplasms | 1 | 2016 | 95 | 0.110 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 142 | 0.110 |
Why?
| | Craniocerebral Trauma | 1 | 2017 | 179 | 0.110 |
Why?
| | Regression Analysis | 2 | 2018 | 1001 | 0.110 |
Why?
| | Family | 2 | 2024 | 685 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2018 | 249 | 0.110 |
Why?
| | Deep Brain Stimulation | 1 | 2018 | 220 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1997 | 0.110 |
Why?
| | Dementia | 1 | 2019 | 328 | 0.110 |
Why?
| | Motor Activity | 1 | 2019 | 718 | 0.110 |
Why?
| | Data Collection | 2 | 2022 | 643 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2022 | 2967 | 0.110 |
Why?
| | Craniofacial Abnormalities | 1 | 2015 | 78 | 0.110 |
Why?
| | Hemodynamics | 1 | 2019 | 1118 | 0.100 |
Why?
| | Neonatal Screening | 1 | 2016 | 179 | 0.100 |
Why?
| | Rhinitis | 1 | 2016 | 169 | 0.100 |
Why?
| | Ureteroscopy | 1 | 2014 | 15 | 0.100 |
Why?
| | Patient Readmission | 1 | 2020 | 772 | 0.100 |
Why?
| | Depressive Disorder | 1 | 2017 | 374 | 0.100 |
Why?
| | Physicians | 1 | 2023 | 956 | 0.100 |
Why?
| | Burnout, Professional | 1 | 2021 | 488 | 0.100 |
Why?
| | Urolithiasis | 1 | 2014 | 11 | 0.100 |
Why?
| | Vitamin D Deficiency | 2 | 2015 | 190 | 0.100 |
Why?
| | Aspirin | 2 | 2016 | 406 | 0.100 |
Why?
| | Behavioral Medicine | 1 | 2014 | 39 | 0.100 |
Why?
| | Anxiety Disorders | 1 | 2017 | 371 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2019 | 547 | 0.100 |
Why?
| | Extremities | 1 | 2014 | 142 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 562 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2024 | 1330 | 0.100 |
Why?
| | Eosinophilia | 1 | 2016 | 224 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 2016 | 286 | 0.100 |
Why?
| | Chronic Disease | 2 | 2016 | 1812 | 0.100 |
Why?
| | Retinopathy of Prematurity | 1 | 2016 | 181 | 0.100 |
Why?
| | Internet | 2 | 2024 | 693 | 0.100 |
Why?
| | Airway Obstruction | 1 | 2015 | 153 | 0.100 |
Why?
| | Demography | 1 | 2014 | 282 | 0.100 |
Why?
| | Pulmonary Ventilation | 1 | 2013 | 82 | 0.100 |
Why?
| | Tonsillectomy | 1 | 2015 | 105 | 0.090 |
Why?
| | Length of Stay | 2 | 2025 | 1350 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2024 | 2064 | 0.090 |
Why?
| | Primary Prevention | 1 | 2015 | 222 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 1150 | 0.090 |
Why?
| | Birth Weight | 1 | 2016 | 517 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 769 | 0.090 |
Why?
| | Refugees | 1 | 2014 | 83 | 0.090 |
Why?
| | Calcinosis | 1 | 2014 | 234 | 0.090 |
Why?
| | Coronary Vessels | 1 | 2014 | 246 | 0.090 |
Why?
| | Mental Disorders | 1 | 2021 | 1169 | 0.090 |
Why?
| | Prognosis | 4 | 2023 | 4329 | 0.090 |
Why?
| | Movement | 1 | 2014 | 293 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2770 | 0.090 |
Why?
| | Teaching Rounds | 1 | 2013 | 74 | 0.090 |
Why?
| | Weight Gain | 1 | 2016 | 561 | 0.090 |
Why?
| | Coronary Disease | 1 | 2014 | 382 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 2000 | 0.090 |
Why?
| | Curriculum | 1 | 2019 | 1074 | 0.090 |
Why?
| | Prospective Studies | 6 | 2025 | 8075 | 0.090 |
Why?
| | Anxiety | 3 | 2026 | 1122 | 0.080 |
Why?
| | Environmental Monitoring | 1 | 2013 | 347 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 444 | 0.080 |
Why?
| | Interpersonal Relations | 1 | 2014 | 398 | 0.080 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 303 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 303 | 0.080 |
Why?
| | Tissue Donors | 1 | 2014 | 420 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2022 | 3416 | 0.080 |
Why?
| | Internal Medicine | 1 | 2013 | 279 | 0.080 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 245 | 0.080 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 130 | 0.080 |
Why?
| | Age of Onset | 2 | 2023 | 557 | 0.080 |
Why?
| | Tissue and Organ Procurement | 1 | 2014 | 343 | 0.080 |
Why?
| | Surveys and Questionnaires | 6 | 2019 | 6085 | 0.080 |
Why?
| | Polysomnography | 3 | 2015 | 239 | 0.070 |
Why?
| | Obesity | 2 | 2021 | 3118 | 0.070 |
Why?
| | Cross Infection | 1 | 2012 | 260 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2023 | 3634 | 0.070 |
Why?
| | Models, Statistical | 1 | 2013 | 672 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3170 | 0.070 |
Why?
| | Health Status | 1 | 2014 | 835 | 0.070 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 750 | 0.070 |
Why?
| | Quality of Health Care | 1 | 2013 | 693 | 0.070 |
Why?
| | Calcium | 1 | 2014 | 1191 | 0.070 |
Why?
| | Sex Factors | 2 | 2026 | 2110 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1269 | 0.070 |
Why?
| | Asthma | 3 | 2016 | 1797 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1331 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1782 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2017 | 2977 | 0.070 |
Why?
| | Urban Population | 2 | 2025 | 494 | 0.060 |
Why?
| | Cardiac Surgical Procedures | 1 | 2013 | 611 | 0.060 |
Why?
| | Patient Participation | 2 | 2022 | 446 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1791 | 0.060 |
Why?
| | Lung Diseases | 1 | 2013 | 782 | 0.060 |
Why?
| | Recurrence | 2 | 2020 | 1139 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1276 | 0.060 |
Why?
| | Intensive Care Units | 1 | 2012 | 924 | 0.060 |
Why?
| | Animals | 2 | 2025 | 38097 | 0.060 |
Why?
| | Influenza, Human | 1 | 2011 | 624 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1378 | 0.060 |
Why?
| | Critical Illness | 1 | 2012 | 900 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2013 | 910 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1420 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2019 | 1115 | 0.050 |
Why?
| | Research Design | 2 | 2021 | 1139 | 0.050 |
Why?
| | Neurologists | 1 | 2024 | 23 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1662 | 0.050 |
Why?
| | Amyloidogenic Proteins | 1 | 2023 | 16 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 56 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 25 | 0.050 |
Why?
| | American Heart Association | 1 | 2025 | 358 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1751 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1711 | 0.050 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 314 | 0.050 |
Why?
| | Primary Health Care | 1 | 2014 | 1737 | 0.050 |
Why?
| | Death | 1 | 2024 | 132 | 0.050 |
Why?
| | Tremor | 1 | 2024 | 98 | 0.050 |
Why?
| | Vaccination | 1 | 2011 | 1428 | 0.050 |
Why?
| | Myelin P0 Protein | 1 | 2022 | 7 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2025 | 251 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1582 | 0.050 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 125 | 0.050 |
Why?
| | Imipramine | 1 | 2022 | 11 | 0.050 |
Why?
| | tau Proteins | 1 | 2023 | 105 | 0.050 |
Why?
| | Organ Size | 1 | 2023 | 461 | 0.050 |
Why?
| | Pain | 2 | 2018 | 791 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 971 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1957 | 0.040 |
Why?
| | Facial Expression | 1 | 2022 | 75 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 428 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 219 | 0.040 |
Why?
| | Polymerization | 1 | 2022 | 127 | 0.040 |
Why?
| | Vagus Nerve | 1 | 2022 | 92 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 177 | 0.040 |
Why?
| | Catalysis | 1 | 2022 | 305 | 0.040 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.040 |
Why?
| | Oncology Service, Hospital | 1 | 2021 | 15 | 0.040 |
Why?
| | Interneurons | 1 | 2022 | 125 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2123 | 0.040 |
Why?
| | Immune System | 1 | 2022 | 180 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2883 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 176 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 173 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 661 | 0.040 |
Why?
| | Lung | 1 | 2013 | 4116 | 0.040 |
Why?
| | Serine | 1 | 2021 | 143 | 0.040 |
Why?
| | Outpatients | 1 | 2024 | 447 | 0.040 |
Why?
| | Reaction Time | 1 | 2022 | 434 | 0.040 |
Why?
| | Medical Informatics | 1 | 2021 | 100 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 178 | 0.040 |
Why?
| | Astrocytes | 1 | 2022 | 228 | 0.040 |
Why?
| | Electrodes, Implanted | 1 | 2020 | 114 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2021 | 141 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 289 | 0.040 |
Why?
| | Multiple System Atrophy | 1 | 2019 | 8 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 404 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 388 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2023 | 696 | 0.040 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2019 | 18 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2022 | 281 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 674 | 0.040 |
Why?
| | Income | 1 | 2020 | 203 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 42 | 0.040 |
Why?
| | Lewy Body Disease | 1 | 2019 | 33 | 0.040 |
Why?
| | Music | 1 | 2019 | 48 | 0.040 |
Why?
| | Infant | 3 | 2018 | 10090 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 136 | 0.030 |
Why?
| | Logistic Models | 2 | 2014 | 2139 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 88 | 0.030 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 133 | 0.030 |
Why?
| | Phosphorus | 1 | 2018 | 90 | 0.030 |
Why?
| | Gait | 1 | 2021 | 312 | 0.030 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 84 | 0.030 |
Why?
| | Stroke Volume | 1 | 2021 | 655 | 0.030 |
Why?
| | Carnitine | 1 | 2018 | 91 | 0.030 |
Why?
| | Muscle Spasticity | 1 | 2018 | 63 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 544 | 0.030 |
Why?
| | Administration, Oral | 1 | 2020 | 867 | 0.030 |
Why?
| | Health Services | 1 | 2019 | 113 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 872 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 78 | 0.030 |
Why?
| | Gadolinium | 1 | 2018 | 84 | 0.030 |
Why?
| | Neural Pathways | 1 | 2019 | 317 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 169 | 0.030 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 356 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 572 | 0.030 |
Why?
| | Registries | 1 | 2026 | 2410 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2019 | 311 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 577 | 0.030 |
Why?
| | Exophthalmos | 1 | 2016 | 18 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 992 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 8 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 618 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Brain Mapping | 1 | 2019 | 542 | 0.030 |
Why?
| | Neuroimaging | 1 | 2019 | 300 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 19 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 789 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 19 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 973 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 782 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 48 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 157 | 0.030 |
Why?
| | Qualitative Research | 1 | 2024 | 1683 | 0.030 |
Why?
| | Self Efficacy | 1 | 2019 | 413 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2016 | 311 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2016 | 143 | 0.030 |
Why?
| | Sleep Stages | 1 | 2015 | 76 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2017 | 533 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2018 | 444 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2019 | 916 | 0.030 |
Why?
| | Contrast Media | 1 | 2018 | 497 | 0.030 |
Why?
| | Electromyography | 1 | 2017 | 419 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 90 | 0.030 |
Why?
| | Thinness | 1 | 2015 | 100 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 148 | 0.030 |
Why?
| | Age Factors | 1 | 2022 | 3346 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2015 | 81 | 0.030 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 98 | 0.030 |
Why?
| | San Francisco | 1 | 2014 | 60 | 0.030 |
Why?
| | Sampling Studies | 1 | 2014 | 98 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1082 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 123 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1270 | 0.020 |
Why?
| | Sternotomy | 1 | 2013 | 25 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2016 | 6464 | 0.020 |
Why?
| | Pilot Projects | 1 | 2019 | 1897 | 0.020 |
Why?
| | Leukotriene E4 | 1 | 2013 | 24 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 116 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2013 | 18 | 0.020 |
Why?
| | Lithotripsy | 1 | 2014 | 49 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1083 | 0.020 |
Why?
| | Thoracotomy | 1 | 2013 | 88 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2013 | 148 | 0.020 |
Why?
| | Linear Models | 1 | 2015 | 849 | 0.020 |
Why?
| | Hospitals, Teaching | 1 | 2013 | 121 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 145 | 0.020 |
Why?
| | Spirometry | 1 | 2013 | 233 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 267 | 0.020 |
Why?
| | Olfaction Disorders | 1 | 2013 | 70 | 0.020 |
Why?
| | Paranasal Sinuses | 1 | 2013 | 81 | 0.020 |
Why?
| | Vital Capacity | 1 | 2013 | 292 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2014 | 328 | 0.020 |
Why?
| | Gestational Age | 1 | 2016 | 989 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2013 | 450 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 536 | 0.020 |
Why?
| | Paper | 1 | 2011 | 9 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 883 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 770 | 0.020 |
Why?
| | Personnel, Hospital | 1 | 2011 | 30 | 0.020 |
Why?
| | Critical Care | 1 | 2017 | 702 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4090 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2013 | 227 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 316 | 0.020 |
Why?
| | Premature Birth | 1 | 2015 | 390 | 0.020 |
Why?
| | Exercise Test | 1 | 2013 | 630 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 326 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2013 | 719 | 0.020 |
Why?
| | Patient Admission | 1 | 2012 | 220 | 0.020 |
Why?
| | Cause of Death | 1 | 2012 | 471 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1327 | 0.020 |
Why?
| | Recovery of Function | 1 | 2013 | 716 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 1003 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1764 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1850 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2011 | 534 | 0.020 |
Why?
| | Mice | 1 | 2022 | 18355 | 0.010 |
Why?
|
|
Sillau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|